XtalPi

XtalPi Holdings Limited operates as a platform technology company combining quantum physics, artificial intelligence, and robotic automation to transform drug discovery and materials research. Listed on the Hong Kong Stock Exchange in June 2024, XtalPi became the first company to go public under the Chapter 18C listing rules designed for specialist technology firms.

Company Overview

Founded in 2015 by three quantum physicists from the Massachusetts Institute of Technology—Wen Shuhao, Ma Jian, and Lai Lipeng—XtalPi emerged from research applying quantum algorithms to molecular structure prediction. The company has since evolved into a broad R&D platform serving pharmaceutical, materials science, energy, and agricultural technology sectors.

The founding team’s academic background established XtalPi’s distinctive approach: using first-principles quantum calculations to generate high-accuracy molecular data, then training AI models on this data to predict properties of novel compounds. This methodology attracted early attention from global pharmaceutical companies, with Pfizer establishing a 10-year partnership in 2016 after XtalPi achieved 100% accuracy in a blind molecular structure prediction test.

XtalPi maintains R&D centers in Shenzhen (headquarters), Shanghai, Beijing, and Boston, with laboratory facilities exceeding 10,000 square meters. Research and development staff account for over 70% of the workforce.

Core Products

ID4 Platform

The Intelligent Digital Drug Discovery & Development (ID4) platform serves as XtalPi’s central technology offering. The platform integrates quantum physics-based molecular simulation with machine learning models and autonomous wet-lab robotics in a closed-loop system. Key components include:

• ID4Idea™: AI-driven drug discovery platform for target identification and lead optimization
• ID4Gibbs™: High-precision computational chemistry platform for thermodynamic predictions

The platform houses over 200 proprietary AI models trained on millions of compound and reaction data points, including Xreactor (molecular generation), XFEP (free energy perturbation), and CSP (crystal structure prediction).

Intelligent Autonomous Lab Platform

XtalPi has deployed over 300 robotic experiment workstations globally, forming what the company describes as the world’s largest commercially operating AI laboratory workstation cluster. The platform operates 24/7, achieving 5x improvement in researcher efficiency and 40x increase in data collection capacity compared to manual methods.

Specific automation products include:

• XmartChem®: Intelligent synthesis workstation for chemical reactions
• XtalComplete®: Automated crystallization workstation
• ChemPlus®: Desktop solid dispensing system

Technology & Innovation

XtalPi’s technical approach centers on the DMTA cycle (Design, Make, Test, Analyze), where AI models propose molecular designs, quantum calculations rank candidates, and robotic systems execute synthesis and testing. Results feed back into model training through active learning.

The company’s patent portfolio and proprietary datasets provide competitive advantages in predicting molecular properties that traditional computational methods struggle with, including solubility, crystalline polymorphism, and binding affinity.

Market Presence

XtalPi serves over 300 enterprise and research institution clients worldwide. Major pharmaceutical partnerships include:

• Pfizer: Ongoing collaboration since 2016, expanded in June 2025 to develop next-generation small-molecule modeling capabilities
• DoveTree Medicines: Landmark $6 billion collaboration announced August 2025 for AI-driven drug discovery across oncology, immunology, and neurology
• Eli Lilly: Partnership through subsidiary Ailux for bispecific antibody development, valued at up to $345 million
• PharmaEngine: Joint development of PEP08, a PRMT5 inhibitor that received clinical trial approvals in Taiwan and Australia in September 2025

Beyond pharmaceuticals, XtalPi has delivered intelligent laboratory systems to Sinopec Shanghai Research Institute, Fudan University, and the Guangdong Provincial TCM Laboratory (Hengqin Laboratory).

Financial Performance

For fiscal year 2024, XtalPi reported revenue of RMB 266 million, representing 53% year-over-year growth. The intelligent robotics business contributed approximately RMB 163 million, while drug discovery solutions generated around RMB 104 million. Adjusted net loss narrowed 12.5% to RMB 457 million.

In the first half of 2025, revenue surged 404% year-over-year to RMB 517 million, driven by major partnership agreements and expanded automation deployments.

Key Milestones

• 2015: Founded by MIT physicists in Shenzhen
• 2016: Secured 10-year partnership with Pfizer after blind prediction test
• 2021: Completed $400 million Series D funding at approximately $2 billion valuation
• 2024: Listed on HKEX as first Chapter 18C specialist technology company (June 13)
• 2025: Announced $6 billion collaboration with DoveTree Medicines; raised HK$2.08 billion through share placement

Frequently Asked Questions

Is XtalPi a medical robotics company?

XtalPi operates in laboratory automation and AI-driven drug discovery rather than clinical medical robotics. Its robotic systems automate pharmaceutical research experiments, not patient-facing procedures.

What is XtalPi’s stock code?

XtalPi trades on the Hong Kong Stock Exchange under the stock code 2228.HK, with the stock short name XTALPI-P.

How does XtalPi generate revenue?

XtalPi generates revenue through two main business lines: intelligent robotics solutions (laboratory automation equipment and services) and drug discovery solutions (AI-powered research partnerships and milestone payments).